US Stock MarketDetailed Quotes

NVS Novartis AG

Watchlist

99.680
-0.850-0.85%

Close May 28 16:00 ET

99.360
-0.320-0.32%

Pre 05:53 ET

203.39BMarket Cap13.60P/E (TTM)

Novartis AG Stock Forum

life is a blessing

5 hours ago

Esperion Therapeutics Is Now A Top Choice Takeover Target

$Esperion Therapeutics(ESPR.US)$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...

BullnBearTrading

Mar 17 22:23

What Happened Last Trade Day (Mar 15)

Stories you might have missed
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...

Moomoo AI

Jan 31 04:28

Google's disappointing ad sales growth and AMD's lower revenue guidance have hurt investor sentiment, causing their shares to drop. Byron Allen's offer to acquire Paramount Global is seen as beneficial for shareholders, boosting its share price. Novartis AG's lower Q4 earnings and adjusted mid-term guidance have led to a share price decline.

Biggest Stock Movers Today: Paramount Global, Google Parent Alphabet, and More

Moomoo AI

Jan 30 07:49

JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.

Novartis Net Profit Expected to Rise With Outlook in Focus -- Earnings Preview

Meltyy

Jan 18 21:03

M&A Update

Recent M&A activities💰 in January:
$Ambrx Biopharma(AMAM.US)$ acquisition by $Johnson & Johnson(JNJ.US)$
Aiolos Bio acquisition by $GlaxoSmithKline(GSK.US)$
$Harpoon Therapeutics(HARP.US)$ acquisition by $Merck & Co(MRK.US)$
Calypso Biotech acquisition by $Novartis AG(NVS.US)$
What companies will be next? 🤔

Moomoo News Global

Jan 9 05:25

ColumnsBiotech M&A Frenzy: Is the Industry Poised for a Promising Recovery in 2024?

Since last October, the biotech sector has been showing signs of recovery. This trend was underscored by the S&P Biotechnology Select Industry Index, which surged by 4.69% yesterday and jumped to a new high since Aug 2022.On 8 Jan, J&J, Merck, and Novartis each announced a series of acquisition deals, many of which featured premiums of over 100%:
● $Johnson & Johnson(JNJ.US)$ has agreed to pay $2 billion in cash for antib...

Moomoo Recap US

Jan 8 15:06

ColumnsWall Street Today | Boeing Fails to Bring Down Market

RECAP
The $Dow Jones Industrial Average(.DJI.US)$ rebounded after pulling out of a Boeing slump. Indexes opened cautious, but built towards a rebound after the S&P 500 shed 1.5% last week to break a two-month winning streak.
$Dow Jones Industrial Average(.DJI.US)$ climbed 0.58%, the $S&P 500 Index(.SPX.US)$ rose 1.41%, and the $Nasdaq Composite Index(.IXIC.US)$ climbed 2.20%. Large tech stocks led the way; all "Magnificent Seven" stocks were...

Boeing shares fall after CEO admits error

Moomoo AI

Jan 5 07:09

The successful funding round and recent developments bear potential for Lykos Therapeutics to transform mental health treatment. Given the estimated 13 million Americans suffering from PTSD, the introduction of their MDMA-assisted therapy could cater to a significant unmet need.

MDMA Therapy Company Lykos Raises $100M in Series A Funding as It Eyes FDA Approval

Movers and Shakers

Jan 3 14:12

ColumnsVoyager Therapeutics Climb 19%, Extending Rally on Novartis Pact

$Voyager Therapeutics(VYGR.US)$ climbed 19% Wednesday, extending this week's rally that was fueled by the company's recent license pact with a unit of Novartis AG.
On Tuesday, Voyager shares surged as much as 39% after the company said it will receive $100 million up front as part of a license pact with Novartis that includes a $20 million purchase of newly issued equity in Voyager. Voyager will also be eligible to get as much as $...

Meltyy

Oct 30, 2023 01:58

Earnings week ahead: Pfizer

In a report slated to come out before the opening bell on Tuesday, analysts expect EPS and revenue to decline Y/Y for drug making giant $Pfizer(PFE.US)$ . The results will follow better-than-anticipated results from its peer $Novartis AG(NVS.US)$ .
Sell-side analysts are optimistic about the stock, giving it a consensus Buy rating. However, the Seeking Alpha Quant Rating system takes a more cautious approach, viewing the stock as a Hold.
SA author Dair Sansyzbayev h...

Weight-loss drugmakers report strong earnings: Boon or bane?

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Overall